CTNM

Business Context and Reporting Period

Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Contineum is a clinical-stage biopharmaceutical company developing small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. Key assets include PIPE-791 (LPA1R inhibitor for IPF, PrMS, chronic pain) and PIPE-307 (M1R inhibitor for depression and RRMS, partnered with J&J). The company is an Emerging Growth Company and Smaller Reporting Company.

Key Financial Metrics

Note: The company has no product revenue. Interest income is derived from cash and marketable securities.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, were $36.0 million, a $15.1 million increase compared to $20.9 million in the same period in 2024.
  • R&D Expenses: Increased by $12.1 million (to $27.8 million) primarily due to higher contract research organization (CRO) costs for the Phase 2 trial of PIPE-791 (IPF), Phase 1b trials for chronic pain and PET imaging, and the VISTA Phase 2 trial for PIPE-307. Personnel-related expenses also rose by $2.3 million.
  • G&A Expenses: Increased by $3.0 million (to $8.2 million) driven by a $1.6 million increase in stock-based compensation and a $1.2 million increase in personnel costs.
• Net Loss Expansion: Net loss for the six months ended June 30, 2025, was $32.0 million, compared to $17.4 million in the prior year period. This was partially offset by higher interest income ($4.3 million vs. $3.6 million).
• Cash Position: Cash, cash equivalents, and marketable securities decreased from $204.8 million at December 31, 2024, to $175.5 million at June 30, 2025, reflecting operating cash burn and net investment activity.

Guidance, Outlook, and Risks

• Clinical Milestones:
  • PIPE-791: Phase 1b PET trial topline data expected in Q3 2025. Phase 2 global proof-of-concept trial in IPF planned for initiation in Q4 2025. Chronic pain Phase 1b trial topline data expected in H1 2026.
  • PIPE-307: Phase 2 VISTA trial for RRMS fully enrolled; topline data expected in Q4 2025. J&J is recruiting for a Phase 2 trial in Major Depressive Disorder (MDD).
• Liquidity and Capital Resources: Management believes existing cash and marketable securities ($175.5 million) are sufficient to fund operations for at least 12 months from the filing date. The company entered an At-The-Market (ATM) sales agreement in May 2025 for up to $75.0 million. In July 2025 (subsequent event), the company closed an ATM offering raising $8.4 million in net proceeds.
• Risks and Contingencies:
  • Financing Risk: Future funding requirements are significant; failure to secure additional capital could force delays or termination of development programs.
  • Development Risk: Clinical trials may fail to demonstrate safety or efficacy. Regulatory approval is uncertain.
  • Collaboration Risk: The J&J partnership for PIPE-307 involves milestone payments and royalties, but J&J has the right to discontinue development or terminate the agreement.
  • Tax Law Changes: Potential impacts from new tax legislation (e.g., OBBB Act) regarding R&D expense deductibility.

Investor Verification Checklist

• Cash Runway: Verify the 12-month liquidity projection against the current burn rate of approximately $30 million per six months in operating cash flow.
• PIPE-791 Trial Costs: Confirm the specific budget and timeline for the upcoming Phase 2 IPF trial, which is a primary driver of increased R&D spend.
• ATM Utilization: Monitor the utilization of the $75 million ATM facility and the impact of the recent $8.4 million raise on share count and dilution.
• J&J Collaboration Status: Track progress of the J&J-led MDD trial and any potential opt-in decisions by Contineum to co-fund Phase 3 development of PIPE-307.
• Stock-Based Compensation: Review the $25.4 million of unrecognized stock-based compensation and its impact on future expense recognition.